Yesterday, scientists presented positive results from our Phase I clinical trial of ALN-PCS at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions held in Chicago. Results showed that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, resulted in statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%.
View our presentation (572 KB PDF) Read our press release (572 KB PDF)Posts Tagged with: Severe Hypercholesterolemia
February 8, 2012
The Scap/SREBP Pathway Is Essential for Developing Diabetic Fatty Liver and Carbohydrate-Induced Hypertriglyceridemia in Animals
January 4, 2012
ALN-PCS Preliminary Phase I Clinical Results
In January 2012, we presented positive preliminary data from our ALN-PCS Phase I study at Brigham and Women’s Hospital in Boston. Data show that ALN-PCS demonstrated robust, statistically significant, and dose-dependent lowering of both PCSK9 and LDL cholesterol levels.
Read our Press Release ALN-PCS Phase I Data Presentation (3.6MB PPT) Listen to Conference CallOctober 27, 2011
Alnylam Podcast Discussing ALN-PCS Phase I Clinical Trial
Dr. Amy Simon, Senior Director of Clinical Research at Alnylam discusses the Phase I clinical study of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.
Listen to Dr. Simon discuss the hypercholesterolemia program (13.7MB mp3) Read our press release ALNY-AASLD-PCS-Oct2010 (2.2MB PDF)September 26, 2011
ALN-PCS Phase I Clinical Trial
In September 2011, we initiated dosing in our Phase I clinical trial with ALN-PCS for the treatment of severe hypercholesterolemia. This study is aimed at evaluating the safety and tolerability of ALN-PCS in subjects with elevated low-density lipoprotein cholesterol (LDLc, or “bad” cholesterol).
Read our press releaseJuly 25, 2011
ALN-PCS Clinical Trial Application
In July 2011, we filed a CTA with the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K. to initiate a Phase I clinical trial with ALN-PCS for the treatment of severe hypercholesterolemia.
Read our press release ALNY-AASLD-PCS-Oct2010 (2.2MB PDF)July 24, 2011
“Alnylam 5×15″ Product Strategy
In January 2011, we were very excited to launch our Alnylam 5×15™RNAi therapeutic product strategy. Alnylam 5×15 was established to focus on the development and commercialization of novel RNAi therapeutics addressing genetically defined diseases with major unmet medical need.
Read our press release Listen to our CEO discuss our 5×15 Strategy (4.7MB MP3) Rare Disease Day podcast (7.2MB MP3)August 11, 2008
